Presentation is loading. Please wait.

Presentation is loading. Please wait.

Midterm results from a physician-sponsored investigational device exemption clinical trial evaluating physician-modified endovascular grafts for the treatment.

Similar presentations


Presentation on theme: "Midterm results from a physician-sponsored investigational device exemption clinical trial evaluating physician-modified endovascular grafts for the treatment."— Presentation transcript:

1 Midterm results from a physician-sponsored investigational device exemption clinical trial evaluating physician-modified endovascular grafts for the treatment of juxtarenal aortic aneurysms  Benjamin W. Starnes, MD, Rachel E. Heneghan, MD, Billi Tatum, RN  Journal of Vascular Surgery  Volume 65, Issue 2, Pages (February 2017) DOI: /j.jvs Copyright © 2016 Society for Vascular Surgery Terms and Conditions

2 Fig 1 Intraoperative imaging depicting deployment of a polytetrafluoroethylene-covered stent into the right renal artery (left panel) and completion imaging for a standard three-vessel physician-modified endovascular graft (PMEG) procedure (right panel). Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

3 Fig 2 Endoleaks by type and number throughout the study period (50 months). Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

4 Fig 3 Physician-modified endovascular graft (PMEG) subject 009 at 2 years demonstrating a typical appearance of dramatic sac regression from preoperatively (left) to follow-up (right). Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

5 Fig 4 Kaplan-Meier survival curves for physician-modified endovascular graft (PMEG). Freedom from all-cause mortality (blue) and aneurysm-related mortality (ARM; red) to 4 years. ∗One patient died of rupture 1 day before being treated. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

6 Fig 5 Freedom from reintervention.
Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

7 Fig 6 Seal zone length in standard endovascular aneurysm repair (EVAR; left) compared with physician-modified endovascular graft (PMEG; right). Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

8 Fig 7 A typical example of a physician-modified endovascular graft (PMEG) device that cannot be manufactured or sold within the United States as a ZFEN device but is easily available under our investigational device exemption (IDE) clinical trial. A, Intraoperative photograph of the actual graft created for a patient with a solitary right kidney and a superior mesenteric artery (SMA) origin that is close to the origin of the right renal artery. B, Preoperative computed tomography angiography axial image. C, Intraoperative angiogram showing successful implantation. D, Axial image at 1 year demonstrating a widely patent SMA and right renal artery. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions


Download ppt "Midterm results from a physician-sponsored investigational device exemption clinical trial evaluating physician-modified endovascular grafts for the treatment."

Similar presentations


Ads by Google